Replies to post #681 on Johnson and Johnson (JNJ)

[Tanis2476]

Depends, you have to look at the coverage of the two products to see if their point is valid. For example, if UnitedHealthcare's formulary phas a step edit in place that states a patient has to fail on Remicade before being able to try Pfizer's biosimilar, then that does indeed limit uptake at least for patients new to taking these drugs. If it is just a matter of a plan like UnitedHealthcare having Remicade in Preferred position vs the Biosimilar being in NonPreferred, than Pfizer's sales force needs to do a better job.